Physician profile
Mark Roque
NPI 1164427043
$475.87
in general payments reported to CMS, 2019-2025
10 companies · $413 in 2025
The $413 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.96 · 2020: $24.55 · 2023: $19.80 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $223.11 | 2025 | Zoryve |
| Collegium Pharmaceutical, INC. | $70.41 | 2025 | Jornay Pm |
| Novo Nordisk INC | $43.51 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $26.58 | 2025 | |
| Tris Pharma INC | $23.59 | 2025 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.80 | 2023 | Xifaxan |
| Cranial Technologies, INC | $19.23 | 2025 | Doc Band |
| Glaxosmithkline, LLC. | $19.11 | 2025 | Rotarix, Penmenvy, Bexsero |
| Corium, LLC | $15.41 | 2025 | Azstarys |
| Merck Sharp & Dohme LLC | $15.12 | 2025 | Gardasil 9, Vaxelis, Rotateq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Roque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.